Search
Feedback
About UniCat 
Help
News
| Listing 1 - 4 of 4 |
Sort by
|
Book
ISBN: 3039288180 3039288172 Year: 2020 Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Abstract | Keywords | Export | Availability | Bookmark
Loading...Choose an application
- Reference Manager
- EndNote
- RefWorks (Direct export to RefWorks)
The influenza virus poses a threat to human health and is responsible for global epidemics every year. In addition to seasonal infections, influenza can cause occasional pandemics of great consequence when novel viruses are introduced into humans. Despite the implementation of comprehensive vaccination programs, influenza viruses continue to pose an important and unpredictable global public health threat. They are one of the most significant causes of morbidity and mortality each year and have a significant economic impact. In recent years, research has been conducted to find alternative approaches to influenza vaccine development, including the generation of universal vaccines. Notably, significant progress in the field of influenza infection, transmission, and immunity have contributed to our understanding of influenza biology, and to expanding the technological approaches for the generation of more efficient strategies against influenza infections. Moreover, highly remarkable developments have been made in the implementation of new methodologies to evaluate the efficiency of vaccines and improve them for use on domestic animals such as poultry, horses, dogs or pigs. This enables us to decrease the exposure of humans to potentially pandemic viruses. The articles in this Special Issue will address the importance of influenza to human health and the advances in influenza research that have led to the development of better therapeutics and vaccination strategies.
heterosubtypic immunity of influenza --- master donor virus --- imprinting --- hemagglutinin --- universal vaccines --- pandemic --- adaptive immunity --- pregnant women --- innate immunity --- antibodies --- Influenza vaccine --- ARDS --- influenza A virus --- humoral response --- influenza vaccine --- original antigenic sin “OAS” --- germinal centers --- immunogenicity --- lung --- epitopes --- Influenza virus --- single nucleotide polymorphisms (SNPs) --- influenza virus --- protein microarray assay --- “universal” influenza vaccine --- vaccination --- influenza --- multiple dimensional assay (MDA) --- infection --- tissue resident --- memory --- vaccines --- CD4 T cell --- broad neutralizing antibody(bnAb) --- hemagglutinin (HA) of influenza virus --- original antigenic sin --- immune response --- morbidity --- T cell --- mPLEX-Flu assay --- Influenza A virus (IAV) --- virus–host interaction --- hemagglutin stalk --- memory B cells --- vaccine safety --- protection efficacy --- live attenuated influenza vaccine --- pediatrics --- vaccination rate
Book
Year: 2020 Publisher: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute
Abstract | Keywords | Export | Availability | Bookmark
Loading...Choose an application
- Reference Manager
- EndNote
- RefWorks (Direct export to RefWorks)
The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation.
Humanities --- Social interaction --- virus-like particle --- influenza A(H1N1)pdm09 --- vaccination --- pregnant women --- antibody titers --- norovirus --- VLP --- vaccine --- genotype --- pre-existing immunity --- cross-reactivity --- blocking antibodies --- original antigenic sin (OAS) --- HPVs --- vaccines --- virus-like particles (VLPs) --- minor capsid protein (L2) --- HCMV --- cytomegalovirus --- nanoparticle --- immune response --- Sudan virus --- mice --- horse --- purified IgG --- long-lived plasma cells --- antibodies --- multivalency --- virus-like particles --- antigenic analysis --- epitope characterization --- hepatitis E vaccine --- serological evaluation --- virion-like epitopes --- well-characterized vaccines --- hepatitis B virus --- surface (envelope) antigen --- sub-viral particle --- capsid --- antigen display --- platform --- viral quantification --- NTA --- flow virometry --- SRFM --- cryo-TEM --- SEM --- plant virus --- virus-like --- vaccine platform --- epitope --- antigen --- cat allergy --- Fel d 1 --- HypoCat™ --- IL-13 --- interleukin-13 --- Tfh cells --- cancer --- immunotherapy --- H7N9 --- pandemic influenza A --- avian flu --- IAV --- VLP vaccine --- n/a
Book
Year: 2020 Publisher: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute
Abstract | Keywords | Export | Availability | Bookmark
Loading...Choose an application
- Reference Manager
- EndNote
- RefWorks (Direct export to RefWorks)
The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation.
virus-like particle --- influenza A(H1N1)pdm09 --- vaccination --- pregnant women --- antibody titers --- norovirus --- VLP --- vaccine --- genotype --- pre-existing immunity --- cross-reactivity --- blocking antibodies --- original antigenic sin (OAS) --- HPVs --- vaccines --- virus-like particles (VLPs) --- minor capsid protein (L2) --- HCMV --- cytomegalovirus --- nanoparticle --- immune response --- Sudan virus --- mice --- horse --- purified IgG --- long-lived plasma cells --- antibodies --- multivalency --- virus-like particles --- antigenic analysis --- epitope characterization --- hepatitis E vaccine --- serological evaluation --- virion-like epitopes --- well-characterized vaccines --- hepatitis B virus --- surface (envelope) antigen --- sub-viral particle --- capsid --- antigen display --- platform --- viral quantification --- NTA --- flow virometry --- SRFM --- cryo-TEM --- SEM --- plant virus --- virus-like --- vaccine platform --- epitope --- antigen --- cat allergy --- Fel d 1 --- HypoCat™ --- IL-13 --- interleukin-13 --- Tfh cells --- cancer --- immunotherapy --- H7N9 --- pandemic influenza A --- avian flu --- IAV --- VLP vaccine --- n/a
Book
Year: 2020 Publisher: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute
Abstract | Keywords | Export | Availability | Bookmark
Loading...Choose an application
- Reference Manager
- EndNote
- RefWorks (Direct export to RefWorks)
The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation.
Humanities --- Social interaction --- virus-like particle --- influenza A(H1N1)pdm09 --- vaccination --- pregnant women --- antibody titers --- norovirus --- VLP --- vaccine --- genotype --- pre-existing immunity --- cross-reactivity --- blocking antibodies --- original antigenic sin (OAS) --- HPVs --- vaccines --- virus-like particles (VLPs) --- minor capsid protein (L2) --- HCMV --- cytomegalovirus --- nanoparticle --- immune response --- Sudan virus --- mice --- horse --- purified IgG --- long-lived plasma cells --- antibodies --- multivalency --- virus-like particles --- antigenic analysis --- epitope characterization --- hepatitis E vaccine --- serological evaluation --- virion-like epitopes --- well-characterized vaccines --- hepatitis B virus --- surface (envelope) antigen --- sub-viral particle --- capsid --- antigen display --- platform --- viral quantification --- NTA --- flow virometry --- SRFM --- cryo-TEM --- SEM --- plant virus --- virus-like --- vaccine platform --- epitope --- antigen --- cat allergy --- Fel d 1 --- HypoCat™ --- IL-13 --- interleukin-13 --- Tfh cells --- cancer --- immunotherapy --- H7N9 --- pandemic influenza A --- avian flu --- IAV --- VLP vaccine
| Listing 1 - 4 of 4 |
Sort by
|